Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Become a doctor or marry a doctor?
WEDX isn't worth trading IMO. Volume has always been horrible (you may want to trade the canadian listing) and the company is impacted too much by the share price of NCST. Also, WEDX needs to fix a number of its production issues at iFire and then hook up with a Chinese partner or two before it'll move significantly higher. Great long-term company if it can get its production problems solved, since iFire will serve an important market - 34-40" flat screen market at bottom basement prices. However for now have fun trading for a few cents.
VRTX up ~$800 million in market cap while IDIX up ~$5 million. Anyone have any opinions or is everyone waiting for the luncheon?
IDIX.... Make sure you weigh IDIX's news out today against VRTX's.
IDIX news just announced on the wire... Bid 10.30 ask 10.85
*DJ Idenix Reports Positive Data From Telbivudine Study
*DJ Idenix: Data From GLOBE Study Suggest Viral Clearance
*DJ IdenixPharm Reports Data From Three Clinical Trials Of Telbivudine
*DJ IdenixPharm 3Q Rev $19.6M Vs $15.6M, +26%>IDIX
*DJ Idenix Announces New 24-Week Data From A Phase IIb Clinical Trial Of Valopicitabine Plus Pegylated Interferon In Treatment Naive Genotype-1 Hepatitis C Patients>IDIX
VRTX is up $8+ in pre-market trading on the PR news...
COR....
http://www.investorshub.com/boards/read_msg.asp?message_id=14315916
COR is dropping the ADHD program for the time being because the upper dose limit the FDA is permitting for CX717 is insufficient for that indication. They will continue with the Alzheimer’s program, which employs much lower dose levels.
COR looks like the big tanker tomorrow...
O/T....Anyone know if there's a VIX (Volatility) Fund (ETF)? I thought I read that you could buy the VIX.
TIA,
10nis
GAPPER = PLAY
PLAY is popping...
O/T.....ADSX / DOC
Press Release Source: Digital Angel Corporation
http://biz.yahoo.com/bw/061025/20061025005372.html?.v=2
Digital Angel Corporation Awarded Patent for Breakthrough Glucose-Sensing RFID Microchip
Wednesday October 25, 10:00 am ET
Implantable Microchip Allows Diabetics to Accurately and Conveniently Monitor Glucose Concentration Levels
SOUTH ST. PAUL, Minn.--(BUSINESS WIRE)--The U.S. Patent and Trademark Office has granted Digital Angel Corporation (AMEX: DOC - News) a patent for its syringe-implantable glucose-sensing RFID microchip, Digital Angel announced today. The RFID microchip measures the glucose concentration levels of diabetic patients and will be marketed and distributed by Digital Angel's sister company, VeriChip, as an extension to the company's products benefiting people.
"A glucose-sensing microchip could profoundly impact the 230 million people worldwide living with diabetes," said Digital Angel CEO and President, Kevin McGrath. "Patent approval for this RFID microchip is a major step in bringing this life-altering technology to market. It also underscores Digital Angel's commitment to innovation, product development and rapid growth."
Checking blood glucose levels regularly is critical to properly managing diabetes. The conventional method - a finger prick - is invasive, painful and often inaccurate. The implantable bio-sensor chip has a passive transponder, glucose sensor and integrated circuitry that allow anyone implanted with the microchip to painlessly scan it to determine their level of glucose concentration. The RFID microchip quickly and accurately transmits the glucose data back to a wireless scanner that displays the glucose level. The RFID microchip is powered by the scanner signal, avoiding the need for a battery in the microchip.
"This is a landmark development in the world of diabetes management," said Dr. Joseph Feldman, Chairman of the Emergency/Trauma Department of Hackensack University Medical Center. "The current process for monitoring blood sugar levels is painful, cumbersome and discouraging, and especially burdensome for the young and the elderly. By having this technology, the process becomes effortless. This glucose-sensing RFID microchip is the next great step in implantable microchip technology."
Digital Angel, a leading producer of electronic tags for livestock, pets, fish and humans, foresees expansion beyond the human market for the glucose-sensing RFID microchip. According to the company, diabetes is a major disease issue in animal livestock today. As a result, the glucose-sensing RFID microchip could have an equally significant impact in monitoring the glucose levels in livestock animals.
"We recognize that extensive work is required to commercialize this product, including the time and investment required for development, clinical trials and FDA approval," said McGrath. "Still, we view this as an incredibly important advancement in the world of diabetes management."
Digital Angel is seeking international patent protection covering the same glucose-sensor RFID technology. The company, in conjunction with VeriChip Corporation, its exclusive licensee in the area of human implantable identification products, is in the process of naming this product.
The patent, No. 7,125,382 was granted on October 24, 2006 and is titled "Embedded Bio-Sensor System."
GAPPER = MO
MO... Moody's upgrade was out this morning... Somebody is making a huge bet on MO going higher tomorrow and I'm going to go with whomever is willing to bet $170 million that it does.
MO...
Something just happened... I've been watching it all day it just popped 2 points on 2+million shares ($170m bet?).... Someone knows something or is trying to make a lot of others think they do.
MO is popping to the upside.... Anyone see any news?
BSX...
Any thoughts on valuation? It's starting to look cheap.
ASH is paying a special dividend of $10.20 tomorrow.
IDIX should be a good play before and after approval because of the huge % of shorts. Based on what I've read and researched IDIX has a very good chance of approval, however, either way some shorts will be covering over the next couple of days and hopefully a lot more if IDIX gets positive news.
Has anyone traded OVTI at all? Always a big mover in both directions and also a large % of shorts.
Good luck,
10nis
Tanker = ASH... hehehehe!!
IDIX looking more and more interesting....news is coming soon!!
UCTT...Looks like a winner and $15+ in the coming weeks. IDIX should be in play very soon (end of this week / early next week).
10nis
LMRA is crashing...
GENR... For whom ever still cares about GENR(I do not).
http://biz.yahoo.com/prnews/061016/phm022.html?.v=65
Press Release Source: Genaera Corporation
Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Monday October 16, 12:33 pm ET
PLYMOUTH MEETING, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today presented new safety data on EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). The data was presented at the Angiogenesis Foundation 4th Annual International Conference being held October 16-17, 2006 at the Sheraton Boston Hotel in Boston, Massachusetts. This data will also be presented by Jack Armstrong, President and CEO of Genaera, at the 2006 BIO InvestorForum being held on October 17-19, 2006 at the Palace Hotel in San Francisco, California.
Dr. Andrew Albright, a Genaera scientist, presented data from recent experiments on the effects of EVIZON on endothelial cell nitric oxide synthase (eNOS), an enzyme involved in maintaining normal blood pressure. Inhibition of eNOS activity is a side-effect of anti-VEGF (vascular endothelial growth factor) drugs, such as Avastin® (bevacizumab), and may be a mechanism that contributes to the hypertension and cardiovascular events seen in patients receiving such drugs. Dr. Albright's work demonstrates that EVIZON does not inhibit VEGF-induced eNOS activity in vitro. In addition, he presented data from 124 patients receiving EVIZON therapy for the treatment of wet AMD in Phase 2 clinical trials showing no clinically significant increase in systolic or diastolic blood pressure.
"This evidence that EVIZON does not inhibit eNOS helps to explain our clinical observations that EVIZON therapy is not associated with hypertension, unlike other anti-angiogenic agents, and suggests it may provide a wider margin of cardiovascular safety," said Michael McLane, Vice President, Non- clinical Development at Genaera Corporation. "Because most anti-angiogenic therapies that inhibit all VEGF pathways also inhibit the beneficial effects of eNOS, these findings underscore the fact that EVIZON exerts activity through specific anti-angiogenic and inflammatory signaling pathways, making it a truly novel member of this class."
To view the data presented at the Angiogenesis Foundation 4th Annual International Conference or the presentation being given at the 2006 BIO InvestorForum, please visit the Company's website at http://www.geneara.com.
IDIX....
What is everyone's prediction on IDIX getting FDA approval at month's end? What kind of stock price do you think IDIX will be trading at if approval is obtained and if its not obtained?
Intersting to see that IDIX has been down the last ten trading sessions.
Thanks,
10nis
ADH...
I'm holding, but I don't have a large % of my portfolio in it. To me its either a home run or a strike out. I'll take my chances holding it.
10nis
IMCL.....
Sanofi-Aventis was unnamed ImClone bidder: NYT
SAN FRANCISCO (MarketWatch) -- Sanofi-Aventis was the unnamed bidder for ImClone Systems Inc. in September, according to a media report Monday. Shares of ImClone (IMCL), a biotechnology company, jumped in the past week after the company revealed in documents released as part of its ongoing squabble with dissident investor Carl Icahn that it had received an attractive takeover bid from an undisclosed pharmaceutical company. See full story.
At that time, ImClone revealed that it had been approached in July by a "major international pharmaceutical company" that was interested in acquiring the biotech group in a stock deal worth $35.50 per share. The suitor raised its bid in September to $36 per share after the board rejected the prior offer as too low.
According to a New York Times story, which cites people involved in the transaction, Paris-based Sanofi-Aventis (SNY), as that unnamed bidder, may have been considering expanding in the United States.
10nis
"All of the shares menitioned in the deal have yet to be officially recorded."
The deal is publicly known and the number of fully diluted shares is known. Thus, if the market is at all efficient the latest LFB partnership news should already be priced into the stock price.
10nis
Cesrph09 "Absurdly cheap"...
Where are you getting a value of $84 million and 84 cents a share? The market current values GTCB at $1.17 x 107 million shares (fully diluted) or roughly $125 million, as Dew mentioned in a previous post.
I'm going to go out on a limb and say that GTCB will either be trading at a stock price higher than $2 within 365 days or it will be acquired for more than $2 in the same period. The company is sitting on too much value for management or the street to understate it for to long, IMO.
I wonder what the stock price would do if the company issued a PR saying they've hired an investment bank to review strategic alternatives. It may just be worth spending a million on investment banking fees to increase the market cap by 50+%.
10nis
Board of directors (BOD)...
Is there anyway that GTCB can attract an investor/shareholder responsible person to the board of directors? Why doesn't the company try to put someone like Dew or someone from Soros Management on the board? Someone that has the best interest of the company in mind but also is a decent size shareholder who cares about the company's share price.
I vote we put Dew on the board.
10nis
Randy - Kramer...
Interesting. It would be great if you could some how throughout GTCB in just talking to him. You could say something like you're a big shareholder in small revolutionary biotechs that George Soros has purchased recently like GTCB and ....., what is your take on big pharma (PFE, MRKs) or big biotech (DNA, AMGN) buying up these companies to advance and expand their pipelines. Should I be investing in these revolutionary biotechs companies that are trading very cheaply for having approved drugs/processes or the potential acquirers? Something like that may get a few people looking into the company.
Good luck and let us know if you are on!!
10nis
Randy - Kramer...
What kind of Booyeaaa did you give him? What did you end up saying? Hopefully you were able to throw GTCB at him.
10nis
"Why do you think this company is eager to get 20% of GTCB?
Because it knows the market and knows that with GTCB it is going to take over this market. Not such a bad deal for GTCB, isn't it?"
Why sell 20% of the company for $1.23 a share? If they wanted GTCB so badly one would think GTCB could have gotten better terms....$1.50 to $2.00/share. The street doesn't seem to like the deal as GTCB is trading down on the news.
10nis
Why doesn't GTCB just sell the company if its going to keep giving itself away? GTCB may close down on this news...
10nis
Quiz answer...
Amgen?
Survey...
Dew - What was your response? I said no, but hoping otherwise.
TIA,
10nis
"That guy calling this a PIPE, obvious basher."
Sorry dude, but I'm not a basher. I've been on this and the biotech values board for awhile. I usually don't have a lot to add since I don't have a lot of technical science knowledge, however, I'm definitely not a basher. I own a significant amount of shares, nothing close to Dew and probably most other people on this board, however, the shares are a good chunk of my investable funds.
10nis
Short position...
Per the WSJ Friday, short position decreased by nearly 1m shares, from roughly 2m shares to 1m. The drop was the 6 largest percentage drop. Looks like the shorting into the PIPE has finally covered.
"They say final authorization on ATryn for use in surgery is expected in September. (is this news?)"
Final authorization was already given. Not news my friend.
OT - CFA
I was one of the lucky 12,314 people that passed the Level III examination.
52 Percent of 63,249 Candidates Worldwide Passed June 2006 Exams for Investment Industry's Highly Regarded CFA Program
A Record 12,314 Who Passed Third and Final Exam Will Soon Join More Than 69,600 Charterholders
CHARLOTTESVILLE, Va., August 16, 2006 – CFA Institute today announced that 52 percent of the 63,249 candidates worldwide in the rigorous Chartered Financial Analyst® (CFA®) program passed the exams they took in June.
To earn the CFA charter, described by many to be the “gold standard” for investment professionals, candidates must sequentially pass three six-hour exams that are widely considered to be among the most challenging in the investment profession. Of the 16,283 individuals who in June 2006 took the third and final exam that leads to the prestigious CFA designation, 12,314 (76 percent) passed.
For the other June 2006 exams, the Level I global pass rate was 40 percent (26,467 took the exam) and the Level II global pass rate was 48 percent (20,499 took the exam). Since the first exam was given in 1963, the average global pass rates are 47 percent for Level I, 52 percent for Level II, and 68 percent for Level III.
“The overall weighted pass rate has moved from 48 percent last year to 52 percent this year,” said Robert Johnson, CFA, Ph.D., managing director of the CFA and CGIPS Programs Division. “We believe this reflects several factors, the most important of which involves better preparation by candidates. Our research suggests that candidates spent more time in preparation for this exam cycle and were more focused on the Body of Knowledge™ from which the examinations are directly derived.
“Candidate success was also aided by the proliferation and variety of available learning materials,” Johnson said. “When I was a CFA candidate in 1990, I was simply given a list of reading materials and had to rely on a large stack of books to study from. Candidates today have access to many more learning tools from CFA Institute, such as Learning Outcome Statements, online sample exams, and the new custom curriculum. The exam has also evolved to reflect the changing nature of the investment industry, which is more complex and global. The CFA examinations reflect this shift because the content is practice-oriented.”
Those who passed the Level III exam – a record 12,314 candidates, which surpasses the last record of 9,410 Level III candidates in 2001 – will begin receiving their CFA charters in early October, provided that they also have completed the minimum work-experience requirement of three years in the investment industry (four years after July 1, 2007), signed a commitment to abide by the CFA Institute Code of Ethics and Standards of Professional Conduct, and become a member of CFA Institute.
“The market recognizes the value of our Code of Ethics and Standards of Professional Conduct and the fiduciary responsibility – putting clients’ interests first – that our members have,” said Jeff Diermeier, CFA, CFA Institute president and CEO. “Employers of investment professionals believe strongly in the value of the CFA program and many require their professional staff to earn the CFA charter. They tell us that they appreciate the depth and breadth of charterholders’ knowledge about investing and financial analysis.”
"The CFA program is increasingly becoming an integral part of our employees' overall investment experience and we continuously promote the CFA program to our employees globally,” said Matthew Scanlan, CFA, head of Americas Institutional Business at Barclays Global Investors. “BGI has always embraced the mission of CFA Institute and is a strong advocate and supporter of the organization’s goals. At BGI, we constantly strive to deliver superior investment performance and we are committed to helping advance the investment industry’s body of knowledge, so CFA Institute is a natural partner for us.”
Employers with the largest number of CFA charterholders, Diermeier noted, include ABN AMRO; Barclays Group; CIBC; Deutsche Bank; Fidelity Investments; The Goldman Sachs Group, Inc.; HSBC; Merrill Lynch & Co., Inc.; Royal Bank of Canada; and UBS.
Exam Results by Country/Region
By country/region, the pass rates for the Level I, Level II, and Level III exams combined are:
United States: 54 percent of the 22,173 total exam candidates
Canada: 53 percent of the 5,914 total exam candidates
Europe: 57 percent of the 10,287 total exam candidates
Asia and Pacific Asia: 49 percent of the 21,109 total exam candidates
Central and South America: 46 percent of the 1,091 total exam candidates
Africa/Middle East: 39 percent of the 2,675 total exam candidates
Thirty-six percent of all CFA candidates for the June exam were from the United States, 21 percent from Pacific Asia, 15 percent from Europe, and 9 percent from Canada. Countries and territories with the largest number of candidates outside North America were Mainland China (5,840), Hong Kong (5,201), United Kingdom (4,807), India (3,178), South Korea (2,919), Singapore (2,726), Taiwan (2,135), Switzerland (1,289), South Africa (1,239), Germany (1,219), and Japan (1,171).
Candidate Enrollment Forecasts
“We estimate there to be 200,000 serious investment professionals in the United States who might qualify for the CFA designation, as well as 90,000 in the United Kingdom and 80,000 in Japan for example, with thousands elsewhere across the globe,” said Timothy G. McLaughlin, CFA, chief financial officer of CFA Institute.
CFA Institute expects more than 121,000 candidate enrollments for the December 2006 and June 2007 CFA exams:
United States: More than 42,000 estimated total candidate enrollments
Canada: More than 10,000 estimated total candidate enrollments
Europe: More than 18,000 estimated total candidate enrollments
Asia and Pacific Asia: More than 42,000 estimated total candidate enrollments
Central and South America: More than 2,000 estimated total candidate enrollments
Africa/Middle East: More than 6,000 estimated total candidate enrollments
“Employer demand for employees with the CFA credential is driving the growth we are seeing in the number of candidates,” Diermeier added.
CFA Program
On average, CFA candidates take four years to pass the three required exams. (The Level I exam is offered twice per year, while the Level II and Level III exams are offered once each year.) The exams cover ethical and professional standards, equity analysis, debt analysis, derivatives analysis, alternative investments, financial statement analysis, quantitative methods, economics, corporate finance, portfolio management, risk management, asset allocation, and performance measurement. CFA Institute recommends at least 250 hours of study per exam. Enrollment information may be found at www.cfainstitute.org/cfaprog/register/index.html.
“The CFA designation is a passport to practice anywhere in the world. The curriculum and examinations are grounded in practice and are regularly reviewed to ensure global relevance,” Johnson said.
There are more than 69,600 CFA charterholders in 120 countries and territories (not counting candidates from the June exams). CFA Institute expects the majority of the 12,314 candidates who passed this year’s Level III exam will become CFA charterholders later this year, bringing the number of charterholders worldwide to more than 79,000.
CFA Institute
CFA Institute is the global, non-profit professional association that administers the Chartered Financial Analyst® curriculum and examination program worldwide, publishes research, conducts professional-development programs, and sets voluntary, ethics-based professional and performance-reporting standards for the investment industry. CFA Institute has more than 84,000 members in 128 countries and territories, including the world’s 69,600 CFA charterholders, as well as 134 affiliated professional societies in 55 countries and territories. CFA Institute has offices in Charlottesville, Va., New York, London, and Hong Kong. More information may be found at http://www.cfainstitute.org.
Why don't you guys bombard Mr. Kramer with emails about GTCB... Maybe he'll almost mention it on his show and GTCB will fly to the moon on the rumor that Kramer may mention it on his next upcoming show. That sounds like a most excellent plan. Or we could just sit back and wait for GTCB to announce some news (partnerships, etc.) and let the positive news flow take care of the stock price.
10nis
ENCY...
http://biz.yahoo.com/pz/060810/103648.html
Press Release Source: Encysive Pharmaceuticals Inc.
Encysive Receives Notification of Marketing Authorization From European Commission Regarding THELIN (Sitaxentan Sodium)
Thursday August 10, 3:18 pm ET
HOUSTON, Aug. 10, 2006 (PRIMEZONE) -- Encysive Pharmaceuticals (NASDAQ:ENCY - News) was notified today that the European Commission has adopted the decision granting marketing authorization for THELIN(r)(1) (sitaxentan sodium(2)) in the European Union.
The Company is awaiting the formal decision letter from the European Commission. Following receipt, which is expected soon, the Company will provide further information.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com.
The Encysive Pharmaceuticals Inc. company logo can be found at http://media.primezone.com/prs/single/?pkgid=843
(1) THELIN is an E.U. registered trademark of Encysive Pharmaceuticals Inc.
(2) ``Sitaxentan'' sodium is the spelling recognized by the World Health Organization for Encysive Pharmaceuticals' sitaxsentan sodium.
o/t: silver nanotech
The company is Nucryst Pharmaceuticals Corp., it was part of Westaim (WEDX) Corp.